ABBV
T3AbbVie Inc.
OverviewAbbVie Inc. discovers, develops, and sells pharmaceuticals globally, focusing on immunology, neuroscience, oncology, and aesthetics. Key products like SKYRIZI a
AbbVie Inc. discovers, develops, and sells pharmaceuticals globally, focusing on immunology, neuroscience, oncology, and aesthetics. Key products like SKYRIZI and RINVOQ drive immunology, while Vraylar and Botox Therapeutic lead neuroscience. Oncology includes VENCLEXTA, and aesthetics features Botox Cosmetic. The company sells to patients through healthcare systems worldwide, with immunology representing over half of its projected 2026 revenue.
- What They Do (Plain English & Analogies)
- AbbVie is like a pharmaceutical powerhouse, constantly searching for, developing, and selling new medicines to treat serious and complex diseases worldwide. Imagine them as a team of highly specialized doctors and scientists who create advanced treatments for conditions ranging from autoimmune diseases (where the body mistakenly attacks itself, like a friendly fire incident) and cancers, to brain disorders like Parkinson's and migraines, and even aesthetic products like wrinkle relaxers. They focus on innovation to bring life-changing solutions to patients.
- Very Brief History
- AbbVie Inc. was formed in 2012 as a corporate spin-off from Abbott Laboratories, becoming a public company in January 2013. A significant milestone in its evolution was the acquisition of Allergan in 2019, which substantially bolstered its presence in aesthetics and neuroscience.
- "Street Stereotype"
- AbbVie is generally perceived by investors and analysts as a large pharmaceutical company successfully navigating the significant revenue loss from its former blockbuster drug, HUMIRA, through the robust growth of its next-generation immunology drugs (SKYRIZI and RINVOQ) and a rapidly expanding neuroscience portfolio. The street also views AbbVie as strategically investing in its pipeline and external innovation to drive long-term growth, with a keen eye on new therapeutic areas like obesity.
- Subsidiaries On Linked In*
- AbbVie Bioresearch Center Inc. — Research-focused entity
- AbbVie Biotherapeutics Inc. — Biotherapeutics development
- AbbVie Endocrinology Inc. — Endocrinology focus
- AbbVie US LLC — U.S. operational entity
- Allergan Sales, LLC — Sales arm for Allergan products
- Knoll Pharmaceutical Company — Historical pharmaceutical entity
- Pharmacyclics LLC — Oncology-focused entity
- ImmunoGen Switzerland GmbH — Swiss entity, likely related to ImmunoGen acquisition
- Pharmacyclics Switzerland GmbH — Swiss entity, likely related to Pharmacyclics
- DJS Antibodies Ltd. — UK-based, acquired for immunology pipeline
- Customer Sectors & Example Clients
- AbbVie's customers are primarily in the healthcare sector, including hospitals, clinics, and pharmacies that administer or dispense their pharmaceutical products. For their aesthetics portfolio, customers include dermatologists, plastic surgeons, and medical spas, as well as individual patients. The company also engages with government entities and specialty pharmacies globally. Due to the nature of the pharmaceutical industry, specific client company names are not publicly disclosed.
- New Customers / Segments They'Re Targeting
- AbbVie is targeting new patient populations through expanded indications for existing drugs, such as RINVOQ for nonsegmental vitiligo and alopecia areata, and for earlier lines of therapy in IBD. In neuroscience, they are targeting patients with early Parkinson's disease with Tavapadon and those with essential tremor with gemmibot A. A significant new segment they are actively entering is the obesity market with their long-acting amylin analog, ABBV 295, aiming to differentiate from existing GLP-1 agonists by focusing on tolerability and muscle mass preservation.
- Supply Chain And Sourcing Geographies
- AbbVie operates a robust and diversified global supply chain with manufacturing facilities in the US and Europe. Their global operations headquarters and a flagship manufacturing facility are located in Lake County, Illinois, USA. They are also investing $1.4 billion to build a new pharmaceutical manufacturing campus in Durham, North Carolina, with construction beginning in 2026. AbbVie purchases goods and services globally and works with overseas suppliers, requiring them to implement security processes and procedures, participating in programs like CTPAT in the U.S.
- Sales Geographies And Expansion Plans
- AbbVie sells its products in over 170 countries worldwide, spanning five world regions. The United States represents the largest portion of its revenue, accounting for 95.17% in fiscal year 2025. While the company has a broad global presence, the transcript does not explicitly state plans to expand sales into entirely new *countries* but rather focuses on expanding market penetration and indications within existing global markets, particularly for products like Vialev in international markets.
- How Key Themes May Help/Hurt
- The 'MedTech Short '25: Heavy China Exposure' theme could potentially hurt AbbVie if it has significant revenue or supply chain dependencies in China, given the ongoing hostility towards China-linked biopharma operations. However, AbbVie's commitment to investing $100 billion in US R&D and capital investments over the next decade, including new US manufacturing facilities, suggests a strategic move to de-risk and strengthen its domestic footprint, which could mitigate some negative impacts. The 'GLP-1 Long '24: Improved Looks' and 'GLP-1 Long '24: Pharma' themes are largely beneficial. AbbVie is actively entering the obesity market with its amylin analog, ABBV 295, aligning with the 'Pharma' subtheme by developing a differentiated treatment. The 'Improved Looks' theme could indirectly boost AbbVie's aesthetics business, as significant weight loss from obesity treatments (including their own amylin analog) often leads to increased demand for cosmetic procedures, a synergy AbbVie aims to capitalize on.
3 Main Long-Term Bull Details
- Dominant and Growing Immunology Franchise: SKYRIZI and RINVOQ are significantly outperforming expectations, with combined sales already surpassing 2027 long-term guidance and projected to grow robustly into the 2030s, driven by new indications and strong market share gains.
- Underappreciated Neuroscience Portfolio with Multi-Billion Dollar Potential: The neuroscience segment is overperforming, with products like Vialev expected to achieve blockbuster status in 2026 and the overall Parkinson's franchise (including Duopa and Tavapadon) having multibillion-dollar peak sales potential. The migraine franchise is also trending significantly above long-term expectations, and a strong pipeline of next-generation assets in psychiatry further solidifies long-term leadership.
- Compelling and Diversified Oncology Pipeline: AbbVie possesses a promising oncology pipeline, including the cMet ADC tmAbA with multibillion-dollar potential across various solid tumors, as well as exciting opportunities with etentamig and follow-on trispecifics in multiple myeloma, and other assets in small cell lung cancer and prostate cancer. Strategic business development is continuously bolstering this portfolio.
3 Main Long-Term Bear Details
- Continued HUMIRA Erosion: Despite the successful launch of successor products, HUMIRA continues to face significant biosimilar competition, leading to ongoing sales declines that create a headwind for overall revenue growth.
- IMBRUVICA Competitive Dynamics and IRA Pricing: The oncology product IMBRUVICA is experiencing competitive pressures and is unfavorably impacted by IRA pricing, leading to anticipated sales declines that will affect the oncology portfolio's growth.
- Aesthetics Market Headwinds: The aesthetics franchise, particularly Juvederm, is facing economic headwinds and challenged market conditions globally, which are expected to persist in 2026, requiring significant investment to stimulate market growth and defend market share against intense competition.
- Competitors And Differentiation
- AbbVie faces competition from major global pharmaceutical companies across its therapeutic areas. In immunology, key competitors include Johnson & Johnson, Pfizer, Roche, Amgen, Eli Lilly, Novartis, Takeda, Sanofi, and UCB (with Bimzelx), as well as biosimilar manufacturers. AbbVie differentiates with SKYRIZI and RINVOQ through demonstrated superior efficacy, durable skin clearance, and convenient dosing, particularly in psoriatic disease and IBD, and by offering a dual-brand strategy in IBD. In oncology, competitors include Roche, AstraZeneca, Merck & Co., Johnson & Johnson, Pfizer, Eli Lilly, and Bristol Myers Squibb. AbbVie aims to differentiate with novel combinations, such as its PD-1 VEGF bispecific antibody with ADCs, and a biomarker-driven approach for some assets. In neuroscience, rivals include Johnson & Johnson, Merck, Pfizer, Roche, Biogen, Boehringer Ingelheim, Eisai, H. Lundbeck, Novartis, Otsuka, Sanofi, Teva, and UCB. AbbVie's differentiation comes from 'transformational treatments' like Vialev for Parkinson's, and a pipeline of next-generation assets aiming for improved efficacy and tolerability. In aesthetics, key competitors are Galderma, Johnson & Johnson, Merz Aesthetics, Bausch Health, Revance, and other neurotoxin and filler brands. AbbVie maintains leadership through strong brand recognition (Botox Cosmetic, Juvederm), market share, and investment in market stimulation and pipeline innovation like Trinibot e. In the emerging obesity market, major competitors are Novo Nordisk and Eli Lilly. AbbVie differentiates with its amylin analog (ABBV 295), which offers an alternative mechanism to GLP-1s, potentially providing better tolerability and muscle mass preservation.
- Recent Performance & What The Market'S Focused On
- AbbVie delivered an excellent year in 2025, achieving record net sales and exceeding financial commitments, with full-year adjusted earnings per share of $10 and total net revenues of $61.2 billion (excluding IPR&D expense). The fourth quarter of 2025 saw adjusted EPS of $2.71 and total net revenues of $16.6 billion, driven by robust 14.5% growth from the ex-HUMIRA platform. For 2026, the company anticipates total sales growth of 9.5% and adjusted earnings per share between $14.37 and $14.57. The market is primarily focused on the continued strong performance and growth trajectory of SKYRIZI and RINVOQ, the rapid expansion and potential of the neuroscience portfolio (especially Vialev and the Parkinson's franchise), the advancements in the oncology pipeline, and the strategic entry into the obesity market. Investors are also closely monitoring the impact of ongoing HUMIRA erosion and IMBRUVICA pricing, as well as efforts to revitalize the aesthetics business.
- Revenue Segments And Estimated Mix
- Global Immunology — Mix: ~51.5%; Source: 2026 guidance; Trend: Expected sales of $34.5 billion, driven by market growth and share gains for SKYRIZI and RINVOQ, despite continued HUMIRA biosimilar impact.
- Global Neuroscience — Mix: ~18.7%; Source: 2026 guidance; Trend: Expected sales of $12.5 billion, reflecting robust double-digit growth.
- Global Oncology — Mix: ~9.7%; Source: 2026 guidance; Trend: Expected sales of $6.5 billion, with VENCLEXTA growth partially offset by IMBRUVICA competitive headwinds and IRA pricing.
- Global Aesthetics — Mix: ~7.5%; Source: 2026 guidance; Trend: Expected sales of $5 billion, reflecting modest market growth for Botox Cosmetic and continued headwinds for Juvederm.
- Product Brands
- HUMIRA
- SKYRIZI
- RINVOQ
- IMBRUVICA
- VENCLEXTA
- MAVYRET
- CREON
- Synthroid
- Linzess/Constella
- Lupron
- Botox Therapeutic
- ORILISSA
- Duopa
- Duodopa
- Lumigan/Ganfort
- Ubrelvy
- Alphagan/Combigan
- Restasis
- Vraylar
- QULYPTA
- Vialev
- Epkinley
- Elijir
- tmAbA
- etentamig
- ABBV 932
- bretacelacin
- miraclodene
- ABBV 295
- Trinibot e
- ABBV 3A2
- lutekizumab
- ABBV 319
- ABBV 619
- ABBV 706
- ABBV 969
- gemmibot A
- GUBamy
- BOTOX Cosmetic
- Juvederm
- CoolSculpting
Bull / Bear DetailsDespite AbbVie's robust pipeline and strong performance from SKYRIZI and RINVOQ, the company faces significant headwinds from ongoing HUMIRA erosion, IMBRUVICA'
Thesis
Despite AbbVie's robust pipeline and strong performance from SKYRIZI and RINVOQ, the company faces significant headwinds from ongoing HUMIRA erosion, IMBRUVICA's competitive decline, and a challenged aesthetics market. While new assets like Vialev and a broad R&D pipeline offer future growth, increasing competitive intensity, potential pricing pressures, and macro concerns make the bear case more compelling as of April 26, 2026.
Bull case
SKYRIZI and RINVOQ are significantly outperforming expectations, with combined sales already surpassing 2027 long-term guidance and projected for robust growth into the 2030s. Their strong market share across psoriasis, RA, and IBD, coupled with new indications like vitiligo and alopecia areata, provides a powerful and durable growth engine offsetting legacy product declines.
AbbVie's diversified pipeline and strategic business development are yielding new growth drivers. The neuroscience portfolio, particularly Vialev, is overperforming, with the Parkinson's and migraine franchises each projected to exceed $5 billion in peak sales. Significant R&D investments and over $8 billion in BD over two years are securing future growth across immunology, neuroscience, oncology, and obesity.
The company's strong financial position, evidenced by record net sales in 2025 and projected high single-digit revenue growth through 2029, provides substantial capacity for continued investment. With no significant LOEs until the next decade, AbbVie has ample firepower to pursue both early and late-stage opportunities, allowing it to acquire differentiated assets and build new growth platforms.
Bear case
AbbVie faces substantial and accelerating erosion of its legacy blockbusters. HUMIRA global sales were down 26.1% operationally in Q4 2025 due to biosimilar competition, with further access decreases expected in 2026. IMBRUVICA also saw a significant 20.8% decline, impacted by competitive dynamics and IRA pricing, posing a persistent drag on overall oncology portfolio growth.
Increasing competitive intensity and anticipated pricing pressures pose significant headwinds. Low single-digit pricing headwinds are expected for SKYRIZI and RINVOQ in 2026 and beyond. The aesthetics market remains challenged by global economic headwinds, impacting Juvederm sales, and Botox's selection for Medicare negotiation highlights broader regulatory and pricing risks across the portfolio.
Despite some regional stability, AbbVie's exposure to China and broader macro headwinds present ongoing risks. The "MedTech Short '25: Heavy China Exposure" theme suggests continued de facto pressure on companies with China-linked operations. This, combined with general economic challenges impacting discretionary spending in the aesthetics market globally, could lead to sustained revenue drag and market share volatility.
Bull / Bear Case
- Bear Case
- AbbVie faces substantial and accelerating erosion of its legacy blockbusters, with HUMIRA global sales down 26.1% operationally in Q4 2025 due to biosimilar competition, and further decreases expected in 2026. IMBRUVICA also saw a significant 20.8% decline, impacted by competitive dynamics and IRA pricing, posing a persistent drag on overall oncology portfolio growth. The aesthetics market remains challenged by global economic headwinds, impacting Juvederm sales, and Botox's selection for Medicare negotiation highlights broader regulatory and pricing risks across the portfolio, with low single-digit pricing headwinds anticipated for key growth products like SKYRIZI and RINVOQ.
- Bull Case
- AbbVie's immunology franchise, led by SKYRIZI and RINVOQ, is significantly outperforming expectations, with combined sales already surpassing 2027 long-term guidance and projected for robust growth into the 2030s. The company's diversified pipeline, bolstered by over $8 billion in strategic business development, is yielding new growth drivers across neuroscience, oncology, and obesity, including the overperforming Vialev and a migraine franchise expected to exceed $5 billion in peak sales. With no significant loss of exclusivity (LOEs) until the next decade, AbbVie possesses substantial financial capacity to invest in both internal innovation and external opportunities, ensuring sustained high single-digit revenue growth through 2029.
- More Compelling & Why
- Bear. Despite a seemingly reasonable forward P/E ratio of approximately 14x, the stock has significantly underperformed the S&P 500, declining over 11% since the earnings call while the SPY gained over 3%. This indicates the market is more heavily discounting the accelerating erosion of legacy blockbusters and increasing competitive intensity. My view would flip if the aesthetics segment showed a clear and sustained recovery, or if the stock price declined further, making the forward valuation significantly more attractive (e.g., forward P/E below 12x).
Key Factors
| Key Factor | Why It Matters | What To Watch | What It Signals | Where/How To Track | Free Alt Data | Paid Alt Data |
|---|---|---|---|---|---|---|
| Material Decline in SKYRIZI's IBD Frontline Capture Rates | SKYRIZI is a primary growth driver, and a significant loss of frontline market share in the IBD segment to new competitors would directly impact its growth trajectory and future revenue projections. | SKYRIZI's 'in-play capture rates' for new and switching patients in IBD (Crohn's and Ulcerative Colitis), particularly in the frontline setting. Management commentary on competitive impact. | Bearish if SKYRIZI's frontline capture rate in IBD (currently ~75% overall, 80% in Crohn's) shows a material and sustained decline in subsequent quarters. | AbbVie's quarterly earnings calls and investor presentations, as well as competitor earnings calls. | Clinical trial results and regulatory approvals for competing IBD drugs. | IQVIA: Prescription and market share data for IBD biologics, specifically IL-23 inhibitors. |
| Continued Headwinds in Aesthetics Market | Persistent or worsening economic headwinds impacting the aesthetics market, particularly Juvederm sales, signal broader consumer discretionary spending issues and challenges to AbbVie's diversification strategy. | Quarterly Aesthetics global sales, with specific attention to Juvederm's operational growth/decline. Management commentary on global market conditions and the effectiveness of new promotional programs. | Bearish if Juvederm's operational sales decline exceeds 10.8% (Q4 2025 rate) in subsequent quarters, or if overall aesthetics sales miss the full-year 2026 guidance of $5 billion. | AbbVie's quarterly earnings releases and conference calls. | Consumer confidence indices (e.g., University of Michigan Consumer Sentiment, Conference Board Consumer Confidence Index). | Earnest Research: Consumer spending trends on aesthetic procedures and products. |
| Higher-than-Anticipated Pricing Headwinds for SKYRIZI and RINVOQ | While SKYRIZI and RINVOQ are key growth drivers, unexpected or more severe pricing pressure could temper their robust sales growth, impacting overall revenue and margin expansion. | Quarterly commentary on pricing trends for SKYRIZI and RINVOQ. Specific reporting on the magnitude of 'unfavorable price comparison' for RINVOQ beyond Q1 2026. | Bearish if pricing headwinds for either SKYRIZI or RINVOQ are reported as mid-to-high single digits beyond Q1 2026, or if this significantly impacts their projected sales growth. | AbbVie's quarterly earnings releases and conference calls. | Industry reports on drug pricing trends and PBM (Pharmacy Benefit Manager) formulary changes. | MMIT (Managed Markets Insight & Technology): Formulary access and rebate data for immunology drugs. |
| IMBRUVICA Sales Decline Due to Competition and IRA Pricing | IMBRUVICA's accelerated decline from competitive dynamics and the impact of IRA pricing will negatively affect the oncology segment's growth and overall company revenue. | Quarterly IMBRUVICA global sales figures and operational growth/decline rates. Management commentary on the specific impact of IRA pricing. | Bearish if IMBRUVICA's operational sales decline worsens beyond 20.8% (Q4 2025 rate) in subsequent quarters, or if the full-year 2026 guidance of $2.2 billion is missed. | AbbVie's quarterly earnings releases and conference calls. | CMS announcements regarding drug price negotiations under the Inflation Reduction Act (IRA). | Symphony Health Solutions: Prescription data for IMBRUVICA and competing BTK inhibitors. |
| Accelerated HUMIRA Sales Erosion | Faster-than-expected decline in HUMIRA sales due to biosimilar competition directly impacts AbbVie's overall revenue and profitability, signaling a more challenging transition post-LOE. | Quarterly HUMIRA global sales figures and operational growth/decline rates. Specific commentary on the pace of biosimilar contract shifts in 2026. | Bearish if HUMIRA's operational sales decline exceeds 26.1% (Q4 2025 rate) in subsequent quarters, or if the full-year 2026 guidance of $2.9 billion is missed. | AbbVie's quarterly earnings releases and conference calls. Next earnings call for Q1 2026 results. | FDA biosimilar approval and launch announcements for adalimumab biosimilars. | IQVIA: Prescription volume and market share data for adalimumab biosimilars versus branded HUMIRA. |
Key Reported Metrics
| Metric | Why It Matters | Last Period |
|---|---|---|
| Global Skyrizi Net Revenues | Skyrizi is a primary growth driver for AbbVie's immunology portfolio, essential for offsetting Humira's decline and demonstrating the success of the company's diversified product strategy. | 32.5% |
| Global Humira Net Revenues | Humira's performance is crucial due to ongoing biosimilar competition. Its decline rate directly impacts the need for growth from newer drugs to offset the revenue erosion. | -25.9% |
| Total Net Revenues | Total revenue indicates AbbVie's overall financial health and growth trajectory, especially as it navigates the impact of Humira's loss of exclusivity. Investors watch this for top-line performance. | 10.0% |
Key QuestionsWill the combined sales decline of HUMIRA and IMBRUVICA in Q1 2026 exceed management's guidance, indicating a faster-than-anticipated erosion of legacy assets?
Will the combined sales decline of HUMIRA and IMBRUVICA in Q1 2026 exceed management's guidance, indicating a faster-than-anticipated erosion of legacy assets?
- Question 2
Will SKYRIZI's frontline capture rates in the IBD market materially decline in Q1 2026 due to increasing competition, challenging its projected growth trajectory?
- Question 3
Will the aesthetics segment's Q1 2026 performance be further constrained by economic headwinds, or will the Medicare negotiation for Botox introduce unexpected short-term pricing or operational challenges?
Rerating Thresholds
| Metric | What'S Needed For Rerating | Why It Matters | Earnings Date |
|---|---|---|---|
| Total Net Revenues | Total Net Revenues growth for Q1 2026 falls below the analyst consensus of 10.8% year-over-year, or AbbVie revises its full-year 2026 revenue growth guidance below 9.5%. | A miss on Total Net Revenues growth would signal that the strong performance of key immunology assets like SKYRIZI and RINVOQ is not sufficiently offsetting the accelerating erosion of legacy blockbusters such as HUMIRA and IMBRUVICA, along with persistent challenges in the aesthetics market. This would validate the existing bearish thesis, indicating that AbbVie's transition strategy is facing more significant headwinds than anticipated, impacting future profitability and competitive positioning. | 2026-04-29 |
| Global Humira Net Revenues | For a lower rerating (strengthening the short thesis), Global Humira Net Revenues for Q1 2026 would need to fall below the Zacks Consensus Estimate of $697 million. This would indicate a decline greater than the -25.9% reported in Q4 2025, or a revised full-year 2026 guidance below the anticipated $2.9 billion. | A worse-than-expected decline in Humira net revenues signals an accelerated erosion of this legacy blockbuster due to biosimilar competition. This directly impacts AbbVie's overall revenue and profitability, highlighting a more challenging transition away from its former top-selling drug and reinforcing concerns about the company's ability to offset these losses with new growth drivers. | 2026-04-29 |
| Global Skyrizi Net Revenues | Global Skyrizi Net Revenues for Q1 2026 falling below the analyst consensus of approximately $4.4 billion. Additionally, a year-over-year growth rate for Skyrizi in Q1 2026 significantly below the 20% projected for the combined Skyrizi and Rinvoq franchise for the full year 2026. | A miss on Skyrizi's revenue or a significant deceleration in its growth rate would signal that competitive pressures, particularly from new oral psoriasis treatments like J&J's Icotyde, or pricing headwinds are impacting this key growth driver more than anticipated. This would undermine AbbVie's post-Humira growth narrative and strengthen the bear thesis regarding the erosion of its immunology franchise. | 2026-04-29 |
Earnings Transcript Summary
· 2025Q4 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 1. **Sustaining strong growth through key immunology assets (SKYRIZI and RINVOQ) and diversifying the portfolio:** Management emphasized that SKYRIZI and RINVOQ combined sales already exceeded their 2027 long-term guidance and are expected to grow robustly into the 2030s. They also highlighted the strong performance and future potential of neuroscience (Vialev, migraine franchise) and oncology assets as underappreciated growth drivers. 2. **Advancing and expanding the pipeline through internal R&D and strategic business development:** Management detailed significant investments in R&D (nearly $1 billion increase in 2025) across 90 clinical programs and over $5 billion in new business development, including promising mechanisms and technologies in immunology, neuroscience, and oncology (e.g., in vivo CAR T, bradicilacin, PD-1 VEGF bispecific). 3. **Commitment to patient access, affordability, and innovation in the US:** Robert Michael mentioned a voluntary agreement with the US government to offer low prices in Medicaid, expand direct-to-patient cash pay options, and commit $100 billion in US R&D and capital investments over the next decade, balancing affordability with protecting innovation. | The overall takeaway of the call was highly positive and confident. Management expressed strong satisfaction with 2025 performance, exceeding financial commitments and delivering record net sales despite HUMIRA erosion. They provided an optimistic outlook for 2026, forecasting robust sales growth driven by SKYRIZI and RINVOQ, and highlighted the underappreciated potential of their neuroscience and oncology pipelines. The tone was consistently upbeat, emphasizing strong execution, pipeline advancement, strategic business development, and a solid financial position to drive sustained long-term growth. | In Q3 2025, AbbVie's immunology portfolio increased by 11.9% on a reported basis. Specifically, SKYRIZI global net revenues increased by 46.8%, and RINVOQ global net revenues increased by 35.3%. HUMIRA global net revenues decreased by 55.4%. The neuroscience portfolio saw a 20.2% increase. The oncology portfolio experienced a 0.3% decrease on a reported basis, or 1.3% on an operational basis. IMBRUVICA revenues fell by 14.8%, while VENCLEXTA increased by 7.1% on a reported basis, or 4.9% on an operational basis. The aesthetics portfolio decreased by 3.7%. | 1. **Psychedelic in development (bradicilacin) opportunity:** David Risinger asked for more details on the psychedelic. Roopal Thakkar responded that it's a potential breakthrough therapy working through the 5-HT2A serotonergic pathway, offering a short-acting hallucination period, immediate and durable efficacy, and high remission rates, differentiating it from other medications. 2. **Immunology franchise (SKYRIZI in IBD and long-term potential of SKYRIZI/RINVOQ):** Christopher Schott questioned SKYRIZI's new start share amidst Tremfya's entry in IBD and if the market fully understands the long-term potential of SKYRIZI and RINVOQ. Jeffrey Stewart stated stable and high new patient capture rates for SKYRIZI in IBD, especially frontline (80% in Crohn's), and overall IL-23 category expansion. Robert Michael added that the combined guidance for SKYRIZI and RINVOQ already exceeds 2027 estimates, and their longer-term growth into the 2030s is underappreciated by the Street. 3. **External innovation/BD lens and RINVOQ/Lutekizumab Phase III HS data:** Terence Flynn inquired about AbbVie's business development strategy (size/risk profile of deals) and expectations for upcoming HS data. Robert Michael explained their focus on early-stage opportunities for growth in the next decade but confirmed willingness to invest in differentiated late-stage assets in core areas. Roopal Thakkar outlined expectations for RINVOQ to overperform in HS (treatment failure population) and Lutekizumab to show high efficacy in naive patients, aiming for a similar 'pair' strategy as in IBD. | Immunology total revenues approximately $8.6 billion (not specified y/y, but SKYRIZI and RINVOQ combined sales increased by more than $8 billion year-over-year for the full year 2025). SKYRIZI total sales were $5 billion, reflecting operational growth of 31.9%. RINVOQ total sales were nearly $2.4 billion, reflecting operational growth of 28.6%. HUMIRA global sales were more than $1.2 billion, down 26.1% on an operational basis. Neuroscience full-year revenues were more than $10.7 billion, reflecting absolute sales growth of nearly $1.8 billion. In the quarter, total revenues were more than $2.9 billion, up 17.3% on an operational basis. VENCLEXTA global sales were $710 million, up 6.4% on an operational basis. IMBRUVICA was down 20.8%. Oncology total revenues were nearly $1.7 billion in the quarter, down 2.5% on an operational basis. Aesthetics global sales were nearly $1.3 billion in the quarter, down 1.2% on an operational basis. BOTOX Cosmetic global revenues were $717 million, up 3.8% on an operational basis. Juvederm global sales were $249 million, down 10.8% on an operational basis. |
Transcript Tidbits
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| AbbVie obtained several new product and indication approvals in 2025, including RINVOQ for GCA, EMERALIS for nonsquamous, non-small cell lung cancer, and Epkinle for second-line follicular lymphoma. Regulatory applications for RINVOQ in nonsegmental vitiligo were recently submitted, with an approval decision in the US anticipated in the fourth quarter, and for alopecia areata in Europe and Japan, with a US submission planned for the second quarter. The IBD market is robust with high single-digit growth, driven by increasing biologic penetration and rapidly expanding lines of therapy. Vialev is expected to achieve blockbuster status in 2026 as a transformational treatment for Parkinson's, and the Parkinson's franchise, including BioLeb, Duopa, and Tivapadon, is projected to achieve peak sales in excess of $5 billion. The migraine franchise is also expected to exceed $5 billion in peak sales. The aesthetics market is described as highly underpenetrated, with efforts to stimulate growth through new promotional programs and injector training. Trinibot e, a fast-acting short-duration toxin, is expected to be approved in the US later this year. Essential tremor is identified as the most common movement disorder with considerable need for effective therapies. Menstrual migraine is a distinct subtype affecting nearly 15% of women with migraine, with a clear need for more effective treatment. AbbVie is also developing ABBV 295, a long-acting amylin analog for obesity. The vitiligo opportunity for RINVOQ is sized at roughly just above half a billion at peak, noting it is the only systemic agent. | AbbVie faces headwinds from continued HUMIRA erosion and IMBRUVICA IRA pricing. HUMIRA global sales were down 26.1% operationally due to biosimilar competition, and access is expected to decrease further in 2026 as more plans move to exclusive biosimilar contracts. SKYRIZI's total prescription share in the US biologic psoriasis market is over 45% and accelerating, with in-play capture rates of new and switching patients exceeding 55%, four times higher than the next closest competitor. In PSA derm, SKYRIZI is capturing roughly one out of every four in-play patients on biologic across all lines of therapy in the US, differentiating it from emerging options where PSA efficacy is unproven. Despite in-class competition for most of 2025, SKYRIZI's capture rates in IBD remain impressive, especially in the frontline setting, where it has an in-play capture rate of approximately 75% overall for IBD and 80% in Crohn's disease. IMBRUVICA sales were down 20.8% due to continued competitive dynamics. The aesthetics market's category growth is anticipated to remain challenged in 2026 due to economic headwinds. AbbVie is confident in SKYRIZI's leadership in IBD despite growing competition, noting that it's not a zero-sum game with other IL-23s and anticipating a head-to-head study readout versus Entyvio. Regarding migraine, AbbVie asserts its leading position with UBRELVY in acute migraine and QLIPTA as the number one branded drug in episodic oral CGRP for prevention, making it difficult to reconcile competitor claims of high new prescriber share. For RINVOQ in vitiligo, AbbVie believes its strong efficacy and tolerability profile, along with growing familiarity in dermatology, will allow it to compete against potential IL-15 directed therapies. In obesity, AbbVie believes that a substantial number of patients will cycle off existing incretins due to tolerability issues, creating an opportunity for differentiated assets. | The IBD market is described as very robust with high single-digit growth, driven by increasing biologic penetration and rapidly expanding lines of therapy. The aesthetics market globally continues to be impacted by economic headwinds. AbbVie reached a voluntary agreement with the US government that aims to balance affordability and access while protecting the US innovation ecosystem. This agreement includes offering low prices in Medicaid, expanding direct-to-patient cash pay options for select products, and committing $100 billion in US R&D and capital investments over the next decade. Botox was selected for Medicare negotiation, which AbbVie found disappointing given its plasma-derived nature, but stated it was conservatively planned for and does not impact long-term growth guidance. The drug pricing deal with the US government provides exemption from tariffs and future pricing mandates, including avoidance of demonstration projects. | AbbVie is entering 2026 with substantial momentum and is well-positioned for another year of strong growth, anticipating total sales growth of 9.5%. The company expects to deliver high single-digit revenue growth through 2029. Key catalysts across core therapeutic areas are anticipated over the next 24 months, including pivotal data for three additional RINVOQ indications and initial data for the Crohn's combination platform with SKYRIZI in immunology. In neuroscience, key readouts are expected for next-generation assets 932, bretacelacin, and miraclodene. Oncology expects registrational data for etentamig and mid-to-late-stage readouts for tmAbA in several solid tumors. Vialev is expected to achieve blockbuster revenue in 2026, and the Parkinson's franchise, including BioLeb, Duopa, and Tivapadon, is projected to achieve peak sales in excess of $5 billion. The migraine franchise is also expected to exceed $5 billion in peak sales. Next-generation psychiatry assets (962, bradisilacin, emriclidine) are being developed to potentially replace the $5 billion peak of Vraylar at its LOE in 2030. The oncology ADC tmAbA has the potential to be a multibillion-dollar opportunity in CRC alone, with other solid tumors also under consideration. AbbVie has no significant LOEs until the next decade, providing capacity to invest in internal and external innovation. The company is focused on early-stage opportunities to drive growth in the middle part of the next decade, but is also willing to invest in differentiated late-stage assets in its core areas and obesity. The sales impact of Trinibot e is expected to largely accrue to Botox, with significant effects appearing towards the end of 2026 and heavily gating into 2027 and 2028. Phase one data for the long-acting amylin analog ABBV 295 in obesity will be available this year, guiding a phase two program expected to begin near the end of 2026. | Heavy | Emerging themes include advanced therapeutic modalities such as in vivo CAR T platforms in immunology and oncology, and siRNA platforms with applicability across immunology, neuroscience, and oncology. The development of next-generation psychedelics, specifically bradicilacin for depression, also represents an emerging therapeutic area. | Our fourth quarter performance closes out another excellent year for AbbVie, and I am very pleased with the significant progress we made in 2025. We are entering 2026 with substantial momentum and remain well-positioned to deliver another year of strong growth. SKYRIZI and RINVOQ, with combined sales of more than $31 billion, already surpassing our 2027 long-term guidance by half a billion. Given the strong outlook of our diverse portfolio, we are well-positioned to deliver high single-digit revenue growth through 2029. Violet will already achieve our peak sales guidance this year. We have many opportunities to deliver upside to street long-term estimates. With no significant LOEs until the next decade, we have plenty of capacity to invest in both internal and external innovation to drive very strong long-term growth. | Despite nearly $16 billion of US HUMIRA erosion since the LOE. Headwinds from continued HUMIRA erosion and IMBRUVICA IRA pricing. HUMIRA access will decrease further throughout 2026 as more plans move to exclusive biosimilar contracts. IMBRUVICA IRA price pricing will unfavorably impact our oncology portfolio growth in 2026. Economic headwinds have continued to impact market conditions globally, and we anticipate category growth will remain challenged in 2026. We're obviously disappointed that it was selected [Botox for Medicare negotiation] given that it's a plasma-derived product and should have been excluded. The competition is growing very rapidly. And it looks like it's inevitable. It will make an important impact on SKYRIZI. |
Notes
| Date | Comment | Comment Type | Comment Sentiment | Link | IS CHANGE | Price Reaction |
|---|---|---|---|---|---|---|
| 2026-02-04 | AbbVie reported strong Q4 2025 results, exceeding financial commitments, and issued robust 2026 guidance driven by key immunology and neuroscience assets. Despite this positive messaging and pipeline advancements, the stock underperformed the broader market post-earnings, reflecting investor concerns over ongoing HUMIRA erosion, aesthetics challenges, and competitive dynamics for growth drivers. | Earnings Transcript | Neutral | False | -0.99% (vs SPY: -1.15%) |
Upcoming Events
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type |
|---|---|---|---|---|---|---|---|---|
| ABBV_c5da1469 | anticipated in the fourth quarter | 2026-10-01 | 2026-12-31 | US regulatory approval decision for RINVOQ in nonsegmental vitiligo. | Approval would expand RINVOQ's market to a new systemic indication, potentially adding to its multi-billion dollar sales trajectory. | Ticker | 2026-02-04 | earnings_transcript |
| ABBV_ac706a0a | US submission is planned for the second quarter | 2026-04-01 | 2026-06-30 | US regulatory submission for RINVOQ in alopecia areata. | This is a critical step towards potential US market entry for RINVOQ in alopecia areata, a significant dermatological condition. | Ticker | 2026-02-04 | earnings_transcript |
| ABBV_171a2b75 | Over the course of 2026 | 2026-04-26 | 2026-12-31 | Readout of Phase 3 data for both RINVOQ and lutekizumab in hidradenitis suppurativa. | Positive data could lead to new indications for RINVOQ and establish lutekizumab as a lead asset, significantly expanding AbbVie's immunology franchise. | Ticker | 2026-02-04 | earnings_transcript |
| ABBV_1bed7b86 | This year | 2026-04-26 | 2026-12-31 | Data from the Crohn's disease platform study evaluating SKYRIZI in combination with ABBV 3A2 and lutekizumab. | This data could demonstrate superior efficacy for patients, strengthening SKYRIZI's position and AbbVie's overall IBD portfolio, especially for patients who have already received SKYRIZI. | Ticker | 2026-02-04 | earnings_transcript |
| ABBV_dfdda14f | anticipate seeing efficacy results later this year | 2026-04-26 | 2026-12-31 | Efficacy results from dose escalation studies for ABBV 619, an in vivo CD19 CAR T platform for autoimmune diseases. | Positive results could signal a transformative new approach to autoimmune diseases, offering deep and durable remission and a significant long-term growth driver. | Ticker | 2026-02-04 | earnings_transcript |
| ABBV_5d3fb65c | initiating a phase three study this year | 2026-04-26 | 2026-12-31 | Initiation of a Phase 3 study for tmAbA in an all-comers population in combination with bevacizumab for colorectal cancer. | This advances tmAbA into late-stage development for a multibillion-dollar opportunity in CRC, bolstering AbbVie's oncology pipeline. | Ticker | 2026-02-04 | earnings_transcript |
| ABBV_800b4101 | an approval decision is anticipated in the third quarter for tevapadon in Parkinson's disease. | 2026-07-01 | 2026-09-30 | US commercial approval decision for tevapadon in Parkinson's disease. | Approval would add a new, potentially multibillion-dollar asset to AbbVie's neuroscience portfolio, offering a new treatment option for Parkinson's disease. | Ticker | 2026-02-04 | earnings_transcript |
| ABBV_47f622ef | data from both trials expected in the second half of this year. | 2026-07-01 | 2026-12-31 | Data readout from Phase 3 studies evaluating QLIPTA and UBRELVY for menstrual migraine prevention. | Positive data could lead to label expansions for these leading migraine products, addressing a distinct and difficult-to-treat subtype of migraine and further driving sales. | Ticker | 2026-02-04 | earnings_transcript |
| ABBV_327b8be4 | data is expected around the middle of this year. | 2026-05-01 | 2026-06-30 | Phase 2 study data readout for ABBV 932 in bipolar depression. | Positive data could position ABBV 932 as a next-generation asset in psychiatry, potentially contributing to the replacement of Vraylar at its LOE in 2030. | Ticker | 2026-02-04 | earnings_transcript |
| ABBV_ced91140 | by Q3 or so | 2026-07-01 | 2026-09-30 | Data from two additional cohorts of a Phase 2 study evaluating bradicilacin in major depressive disorder (MDD). | This data will inform the development strategy and Phase 3 plans, with bradicilacin having the potential to be a groundbreaking new treatment in depression due to its strong efficacy and short-acting profile. | Ticker | 2026-02-04 | earnings_transcript |
| ABBV_cba492a1 | an approval decision is expected this year. | 2026-04-26 | 2026-12-31 | US regulatory approval decision for Trenebody, a rapid-onset short-acting toxin for aesthetics. | Approval and subsequent launch could stimulate the aesthetics market by attracting new patients and ultimately accrue to Botox share, increasing overall revenue. | Ticker | 2026-02-04 | earnings_transcript |
| ABBV_80210779 | we will shortly see a readout over a head-to-head study with Entyvio. | 2026-04-26 | 2026-06-30 | Readout of head-to-head study data for SKYRIZI versus Entyvio in ulcerative colitis. | Positive data could provide a significant opportunity to continue SKYRIZI's momentum and leadership in the IBD market, differentiating it from other competitors. | Ticker | 2026-02-04 | earnings_transcript |